Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues
Reports 82% Growth In Q3
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.
You may also be interested in...
Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales
The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.
Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
How Post-Approval GMP Challenges Cooled Novo Nordisk’s Blazing Wegovy Launch
Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.